Based on our current understanding the complexity of such age-related diseases, employing combination therapy strategy targeting multiple mechanisms involved in the cGMP–PKG pathway, for example, targeting both NO-independent NP–pGC–cGMP and NO-dependent sCG–cGMP pathways, might be able to shed some light in the quest for new therapeutic tools against heart failure. This evidence concerns the gene PRKG1 and heart failure.